ROVI updates its strategy in a meeting with shareholders, investors and analysts
Wed, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Related
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 10% to 303.2 million euros in 2018, driven mainly by the strength of...
5 min
26/02/2019
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has reached an agreement with a subsidiary of MSD (“MSD”) whereby ROVI acquires certain...
2 min
15/02/2019
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.